|Pfizer||External R&D Innovation, Worldwide Research||USA|
Is Europe competitive enough in Life Sciences innovation ?
Dr. Ron Newbold is Vice President of External R&D Innovation (ERDI) at Pfizer and supports numerous global alliances with universities and biotechnology companies, strengthening Pfizer’s access to cutting edge science for Pfizer’s Research division. Ron’s group has responsibility for identifying collaborative opportunities for all their scientific areas of interest (Oncology, Neuroscience, Immunology and Inflammation, Cardiovascular and Rare Diseases) and he also leads the Pfizer Seed Fund, which helps support new spin-out companies of therapeutic interest.
Ron brings to Pfizer significant experience in external partnering in the Life Sciences field from his previous activities at Merck as well as entrepreneurial start-up experience with 3 early-stage biotech companies (Sentigen Biosciences, Celldex Therapeutics, Auspex Pharmaceuticals). Ron earned his MS and PhD in Organic Chemistry from the University of Rochester, completed a postdoctoral fellowship with Nobel Laureate E.J. Corey at Harvard University, and later completed an MBA from the Columbia Business School.